Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma

British Journal of Dermatology

Volumn 164, Issue 4, 2011, Pages 814-821

  Stutz, N ^a   Nihal, M ^a   Wood, Gary S ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; POLO LIKE KINASE 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CUTANEOUS T CELL LYMPHOMA; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; SKIN BIOPSY; TONSIL;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; OBSERVER VARIATION; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953683103     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10128.x     Document Type: Article

References (56)

1. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768-85. (Pubitemid 40656118)
2. Kim YH, Liu HL, Mraz-Gernhard S et al. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139:857-66. (Pubitemid 36898920)
3. Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010; 70:273-86.
4. Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood 2009; 114:4337-53.
5. Golsteyn RM, Mundt KE, Fry AM et al. Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol 1995; 129:1617-28.
6. Ferris DK, Maloid SC, Li CC. Ubiquitination and proteasome mediated degradation of polo-like kinase. Biochem Biophys Res Commun 1998; 252:340-4. (Pubitemid 28542888)
7. Golsteyn RM, Schultz SJ, Bartek J et al. Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 1994; 107:1509-17. (Pubitemid 24198470)
8. Hamanaka R, Smith MR, O'Connor PM et al. Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J Biol Chem 1995; 270:21086-91.
9. Lee KS, Yuan YL, Kuriyama R et al. Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol Cell Biol 1995; 15:7143-51.
10. Toyoshima-Morimoto F, Taniguchi E, Shinya N et al. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 2001; 410:215-20. (Pubitemid 32216594)
11. Roshak AK, Capper EA, Imburgia C et al. The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal 2000; 12:405-11. (Pubitemid 30417604)
12. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996; 135:1701-13. (Pubitemid 27036434)
13. Schmit TL, Ahmad N. Regulation of mitosis via mitotic kinases: new opportunities for cancer management. Mol Cancer Ther 2007; 6:1920-31. (Pubitemid 47052482)
14. Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009; 10:265-75.
15. Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004; 5:429-40. (Pubitemid 38745493)
16. Smith MR, Wilson ML, Hamanaka R et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997; 234:397-405. (Pubitemid 27243915)
17. Simizu S, Osada H. Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nat Cell Biol 2000; 2:852-4.
18. Takai N, Miyazaki T, Fujisawa K et al. Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett 2001; 164:41-9. (Pubitemid 32144988)
19. Gray PJ Jr, Bearss DJ, Han H et al. Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 2004; 3:641-6. (Pubitemid 39193743)
20. He ZL, Zheng H, Lin H et al. Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol 2009; 15:4177-82.
21. Ito Y, Miyoshi E, Sasaki N et al. Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer 2004; 90:414-18. (Pubitemid 38250638)
22. Ito Y, Nakamura Y, Yoshida H et al. Polo-like kinase 1 expression in medullary carcinoma of the thyroid: its relationship with clinicopathological features. Pathobiology 2005; 72:186-90. (Pubitemid 41225243)
23. Jang YJ, Kim YS, Kim WH. Oncogenic effect of polo-like kinase 1 expression in human gastric carcinomas. Int J Oncol 2006; 29:589-94.
24. Knecht R, Oberhauser C, Strebhardt K. PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer 2000; 89:535-6.
25. Kneisel L, Strebhardt K, Bernd A et al. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002; 29:354-8.
26. Schmit TL, Zhong W, Nihal M et al. Polo-like kinase 1 (Plk1) in non-melanoma skin cancers. Cell Cycle 2009; 8:2697-702.
27. Schmit TL, Zhong W, Setaluri V et al. Targeted depletion of pololike kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 2009; 129:2843-53.
28. Strebhardt K, Kneisel L, Linhart C et al. Prognostic value of pololike kinase expression in melanomas. JAMA 2000; 283:479-80. (Pubitemid 30062860)
29. Takahashi T, Sano B, Nagata T et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003; 94:148-52. (Pubitemid 36575873)
30. Takai N, Miyazaki T, Fujisawa K et al. Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett 2001; 169:41-9. (Pubitemid 32532095)
31. Tokumitsu Y, Mori M, Tanaka S et al. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 1999; 15:687-92.
32. Weichert W, Denkert C, Schmidt M et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004; 90:815-21. (Pubitemid 38406592)
33. Weichert W, Kristiansen G, Schmidt M et al. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol 2005; 11:5644-50. (Pubitemid 41684917)
34. Weichert W, Kristiansen G, Winzer KJ et al. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch 2005; 446:442-50. (Pubitemid 40674853)
35. Weichert W, Schmidt M, Gekeler V et al. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004; 60:240-5. (Pubitemid 38971835)
36. Weichert W, Schmidt M, Jacob J et al. Overexpression of polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology 2005; 5:259-65. (Pubitemid 40754747)
37. Weichert W, Ullrich A, Schmidt M et al. Expression patterns of pololike kinase 1 in human gastric cancer. Cancer Sci 2006; 97:271-6.
38. Wolf G, Elez R, Doermer A et al. Prognostic significance of pololike kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997; 14:543-9. (Pubitemid 27090956)
39. Liu L, Zhang M, Zou P. Expression of PLK1 and survivin in diffuse large B-cell lymphoma. Leuk Lymphoma 2007; 48:2179-83. (Pubitemid 350091059)
40. Liu L, Zhang M, Zou P. Polo-like kinase 1 as a new target for non-Hodgkin's lymphoma treatment. Oncology 2008; 74:96-103. (Pubitemid 351915016)
41. Mito K, Kashima K, Kikuchi H et al. Expression of polo-like kinase (PLK1) in non-Hodgkin's lymphomas. Leuk Lymphoma 2005; 46:225-31. (Pubitemid 40185952)
42. Knecht R, Elez R, Oechler M et al. Prognostic significance of pololike kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59:2794-7. (Pubitemid 29283110)
43. Feng YB, Lin DC, Shi ZZ et al. Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer 2009; 124:578-88.
44. Wu J, Nihal M, Siddiqui J et al. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol 2009; 129:1165-73.
45. Guan R, Tapang P, Leverson JD et al. Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005; 65:2698-704. (Pubitemid 40490070)
46. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100:5789-94. (Pubitemid 36576886)
47. Reagan-Shaw S, Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J 2005; 19:611-13. (Pubitemid 40471261)
48. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M et al. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002; 94:1863-77. (Pubitemid 36104631)
49. Thestrup-Pedersen K, Kaltoft K. Genotraumatic T cells and cutaneous T-cell lymphoma. A causal relationship? Arch Dermatol Res 1994; 287:97-101.
50. Padilla-Nash HM, Wu K, Just H et al. Spectral karyotyping demonstrates genetically unstable skin-homing T lymphocytes in cutaneous T-cell lymphoma. Exp Dermatol 2007; 16:98-103. (Pubitemid 46040486)
51. Clay FJ, McEwen SJ, Bertoncello I et al. Identification and cloning of a protein kinase-encoding mouse gene, Plk, related to the polo gene of Drosophila. Proc Natl Acad Sci USA 1993; 90:4882-6. (Pubitemid 23182939)
52. Georgescu SP, Komuro I, Hiroi Y et al. Downregulation of polo-like kinase correlates with loss of proliferative ability of cardiac myocytes. J Mol Cell Cardiol 1997; 29:929-37. (Pubitemid 27196520)
53. Hamanaka R, Maloid S, Smith MR et al. Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ 1994; 5:249-57. (Pubitemid 24251374)
54. Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009; 14:559-70.
55. Schöffski P, Blay JY, De Greve J et al. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer 2010; 46:2206-15.
56. Chopra P, Sethi G, Dastidar SG, Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs 2010; 19:27-43.